Benjamin Suttle

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde et al. · The Lancet Oncology · 2018 · 614 citations

Medicine, Oncology, Pharmacology +12

A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features

Clémentine Sarkozy, Franck Morschhauser, Sydney Dubois et al. · Clinical Cancer Research · 2020 · 76 citations

Medicine, Oncology, Pharmacotherapy +13

Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors

Herbert I. Hurwitz, Afshin Dowlati, S. Savage et al. · Journal of Clinical Oncology · 2005 · 74 citations

Medicine, Pharmacology, Clinical Pharmacology +1

Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).

Johanna C. Bendell, Chloé E. Atreya, Thierry André et al. · Journal of Clinical Oncology · 2014 · 63 citations

Medicine, Oncology, Pharmacology +17

Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory <i>BRAF</i> V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST).

Mark W. Kieran, Darren Hargrave, Kenneth J. Cohen et al. · Journal of Clinical Oncology · 2015 · 34 citations

Medicine, Oncology, Pharmacology +14